Is lacosamide approved for pediatric use?

Is lacosamide approved for children?

Lacosamide (Vimpat) is approved in at least some pediatric age groups. In the European Union, it is approved for pediatric patients from 4 years of age for partial-onset (focal) seizures. [1]

What pediatric age range is covered?

The EU indication specifies use in children aged 4 years and older with partial-onset seizures. [1]

Is it approved for all seizure types in pediatrics?

The pediatric approval is for partial-onset (focal) seizures, not all seizure categories. [1]

Where can I confirm the latest label/indication?

Check the most recent prescribing information or drug label, and regional regulator updates for your country. For a cross-check on patents and market context, DrugPatentWatch.com can also help track lacosamide’s commercial landscape. [2]

Sources cited

[1] https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat
[2] https://www.drugpatentwatch.com/